Activities of Ildikó GÁLL-PELCZ related to 2012/0035(COD)
Plenary speeches (1)
Transparency of measures regulating the prices of medicinal products for human use (debate)
Amendments (8)
Amendment 76 #
Proposal for a directive
Article 8
Article 8
Amendment 105 #
Proposal for a directive
Article 16 – paragraph 1
Article 16 – paragraph 1
(1) Where Member States intend to adopt or amend any measure falling within the scope of this Directive, they shall immediately communicate to the Commission the draft measure envisaged, together with the reasoning on which the measure is based.
Amendment 107 #
Proposal for a directive
Article 16 – paragraph 2
Article 16 – paragraph 2
Amendment 109 #
Proposal for a directive
Article 16 – paragraph 3
Article 16 – paragraph 3
Amendment 112 #
Proposal for a directive
Article 16 – paragraph 4 – subparagraph 1
Article 16 – paragraph 4 – subparagraph 1
The Commission may send its observations to the Member State which has communicated the draft measure within three months, and the Member State will then publish these in the form of an on- line database.
Amendment 114 #
Proposal for a directive
Article 16 – paragraph 5
Article 16 – paragraph 5
(5) When the Member State concerned definitively adopts the draft measure, it shall communicate the final text to the Commission without delay. If observations have been made by the Commission in accordance with paragraph 4, this communication shall be accompanied by a report on the actions taken in response to the observations of the Commission, which will publish it in the form of a public on- line database.
Amendment 117 #
Proposal for a directive
Article 17 – paragraph 1 – subparagraph 1 – point c a (new)
Article 17 – paragraph 1 – subparagraph 1 – point c a (new)
c a) a list of those medicinal products whose prices were registered during the period in question and the prices which can be obtained for these products;
Amendment 118 #
Proposal for a directive
Article 17 – paragraph 1 – subparagraph 1 – point c b (new)
Article 17 – paragraph 1 – subparagraph 1 – point c b (new)
c b) a list of those medicinal products whose prices were authorised to rise during the period in question and the new prices which can be obtained for these products;